Sarepta Therapeutics, Inc. Stock News

NEW YORK , June 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”). Sarepta is a commercial-stage biopharmaceutical company. For more information, subm...

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) securities between June 22, 2023 and June 24,...

Over the past year, Editas Medicine (EDIT -3.20%) and Sarepta Therapeutics (SRPT -1.38%), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Both drugmakers have seen their shares plummet over the trailing-12-month period.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options

Investors can contact the law firm at no cost to learn more about recovering their losses

MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Shamis & Gentile, P.A: To: All persons or entities who purchased or otherwise acquired Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ:SRPT) securities between June 22, 2023, and June 24, 2025, inclusive. You are hereby notified that the class action lawsuit Dolgicer, Jr. v.

Sarepta stock dropped again Wednesday after the FDA announced it's investigating the deaths of two patients who received Elevidys.